![Geert Roels](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Geert Roels
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Okairos AG
![]() Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Geert Roels
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ROCHE HOLDING AG | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
![]() F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
The American University of Rome | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
OMRIX Biopharmaceuticals, Inc.
![]() OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Pharmaceuticals: Major | Director/Board Member | |
CHUGAI PHARMACEUTICAL CO., LTD | Pharmaceuticals: Major | Director/Board Member | |
BIOTIE THERAPIES CORP | Pharmaceuticals: Major | Chairman Director/Board Member | |
University of Freiburg | College/University | Doctorate Degree | |
C.H. Boehringer Sohn AG & Co. KG
![]() C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Hoffmann-La Roche, Inc.
![]() Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal | |
Morphochem AG
![]() Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Miscellaneous Commercial Services | Director/Board Member | |
IDEA AG
![]() IDEA AG Pharmaceuticals: MajorHealth Technology IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Novartis Venture Funds
![]() Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Chief Investment Officer | |
NEOVACS | Pharmaceuticals: Major | Director/Board Member | |
Affectis Pharmaceuticals AG
![]() Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Pharmaceuticals: Major | Chairman | |
Freie Universität Berlin | College/University | Graduate Degree | |
Novartis Vaccines & Diagnostics, Inc.
![]() Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Altimmune UK Ltd.
![]() Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
binx health, inc.
![]() binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member Director/Board Member | |
MyoPowers Medical Technologies France SAS
![]() MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
McKinsey & Co., Inc. (United Kingdom)
![]() McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU. | Investment Managers | Corporate Officer/Principal | |
Okairos SRL
![]() Okairos SRL Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Okairos SRL is an Italian company that manufactures drugs. The company is based in Rome, Italy. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Boehringer Ingelheim RCV GmbH & Co. KG
![]() Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Boehringer Ingelheim RCV GmbH & Co. KG develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments. The company was founded in 1885 by Albert Boehringer and is headquartered in Vienna, Austria. | Biotechnology | Director/Board Member | |
Boehringer Ingelheim International GmbH
![]() Boehringer Ingelheim International GmbH BiotechnologyHealth Technology Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany. | Biotechnology | Corporate Officer/Principal | |
Università degli Studi di Napoli Federico II | College/University | Doctorate Degree | |
Boehringer Ingelheim (Venture Capital)
![]() Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | President | |
LSP Services Deutschland GmbH | Investment Managers | President | |
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
Nouscom AG
![]() Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder Founder Founder | |
Cardior Pharmaceuticals GmbH
![]() Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Imcheck Therapeutics SAS
![]() Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
DNA Script SAS
![]() DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Binx Health Ltd.
![]() Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Miscellaneous Commercial Services | Director/Board Member | |
Vensana Capital Management LLC
![]() Vensana Capital Management LLC Investment ManagersFinance Vensana Capital Management LLC (Vensana Capital) is a venture capital and growth equity investment firm founded in 2019 by Peter Klein Justin & Kirk G. Nielsen. The firm is headquartered in Saint Paul, Minnesota. | Investment Managers | Consultant / Advisor | |
Northern Mosaic LP
![]() Northern Mosaic LP Miscellaneous Commercial ServicesCommercial Services Northern Mosaic LP provides biotechnology technology services. The company is headquartered in Toronto, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
858 Therapeutics, Inc.
![]() 858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Reithera Srl
![]() Reithera Srl Real Estate Investment TrustsFinance ReiThera Srl is a contract development and manufacturing organization (CDMO) based in Rome, Italy. The Italian company specializes in technology and process development, as well as GMP manufacturing, to support the clinical translation of genetic vaccines and medicinal products for advanced therapies. ReiThera has extensive expertise in developing scalable processes for viral-vector manufacturing and has a consolidated experience in GMP production of various types of viral vectors. The company's state-of-the-art facility includes bioreactors of different scales, a filling suite, and quality control laboratories. ReiThera's international team has contributed to several research projects aimed at unlocking the potential of innovative prophylactic and therapeutic programs. ReiThera Srl is dedicated to meeting the highest demand for the development, manufacture, and storage of viral vectors, drugs, and clinical samples. The company was founded in 2005 by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, and Stefano Colloca, who is also the CEO. | Real Estate Investment Trusts | Founder Chief Executive Officer Chief Executive Officer | |
MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Nouscom Srl | Miscellaneous Commercial Services | Director/Board Member | |
Swissvention Partners GmbH | Chief Executive Officer | ||
Amyl Therapeutics SRL
![]() Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Biotechnology | Founder | |
College of Biological Science | College/University | Undergraduate Degree | |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Director/Board Member | |
Priothera SAS
![]() Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Chief Executive Officer | |
EQT Life Sciences (Munich) | Investment Managers | Private Equity Investor |
Statistik
International
Deutschland | 12 |
Vereinigte Staaten | 10 |
Italien | 7 |
Frankreich | 7 |
Schweiz | 6 |
Sektoral
Health Technology | 30 |
Commercial Services | 8 |
Finance | 8 |
Consumer Services | 6 |
Technology Services | 2 |
Operativ
Director/Board Member | 94 |
Chairman | 29 |
Corporate Officer/Principal | 22 |
Founder | 14 |
Independent Dir/Board Member | 10 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Bradley Bolzon | 41 |
Florent Gros | 28 |
William Burns | 27 |
Joachim Rothe | 22 |
Markus Hosang | 15 |
Michel Pairet | 7 |
Alfredo Nicosia | 5 |
Antonella Folgori | 4 |
Cinzia Traboni | 4 |
Stefano Colloca | 3 |
- Börse
- Insiders
- Geert Roels
- Unternehmensverbindungen